5 completed, 1 active not recruiting, 1 recruiting, 1 unknown. 8 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 5 | Completed 3, Active not recruiting 1, Recruiting 1 |
Follow Neoplasms, Lung: new trials by email Literature Review of Neoplasms, Lung trials Research Report on Neoplasms, Lung
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) Risvutatug rezetecan, Ivonescimab - Neoplasms, Lung | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 184 | 2026-09-09 | 2026-09-23 |
| Study of ESG401 in Adults With Solid Tumors ESG401 - Neoplasms, Breast, Neoplasms, Lung | Phase 1 / Phase 2 | Completed | Shanghai Escugen Biotechnology Co., Ltd | 156 | 2021-09-14 | 2025-09-12 |
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 344 | 2021-02-24 | 2026-10-19 |
| The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine cancer stem cell vaccine - Neoplasms, Lung | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 40 | 2014-03-01 | 2019-09-12 |
| Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells cancer stem cell vaccine - Neoplasms, Lung | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 40 | 2014-03-01 | 2015-06-03 |
| A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Erlotinib, Docetaxel, Cisplatin - Neoplasms, Lung, Carcinoma, Non-Small Cell Lung | Phase 2 | Unknown | Chinese PLA General Hospital | 60 | 2010-06-01 | 2010-05-27 |
| Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) - Pulmonary Diseases, Neoplasms, Lung | Phase 2 | Completed | Sanofi | 98 | 2006-01-01 | 2012-12-10 |
| A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. Gemcitabine, Carboplatin, LY900003 - Carcinoma, Non-Small-Cell Lung, Pulmonary Neoplasms | Phase 2 | Completed | Eli Lilly and Company | 2002-06-01 | 2006-07-19 |
Lung Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Disease (1) · Lung Diseases (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Stomach Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms by Site (8) · Respiratory Tract Diseases (8) · Respiratory Tract Neoplasms (8) · Thoracic Neoplasms (8) · Lung Diseases (7) · Neoplasms (7) · Bronchial Neoplasms (4) · Carcinoma, Bronchogenic (4) · Colonic Diseases (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2)
Carboplatin (1) · Cisplatin (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · ISIS 3521 (1) · JDQ443 (1) · aflibercept (1) · tislelizumab (1)
Fuda Cancer Hospital, Guangzhou (2) · Chinese PLA General Hospital (1) · Eli Lilly and Company (1) · GlaxoSmithKline (1) · Novartis Pharmaceuticals (1) · Sanofi (1) · Shanghai Escugen Biotechnology Co., Ltd (1)
China (5) · United States (4) · Canada (2) · France (2) · Japan (2) · Australia (1) · Belgium (1) · Denmark (1) · Germany (1) · Hong Kong (1) · Italy (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1)
Fei Ma (1) · Liang-An Chen, M.D., Ph.D. (1)
PMID 22473314, PMID 20593550, PMID 36399068, PMID 39216478, PMID 40359710